Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasmsC. Pecquet, Stefan N. Constantinescu, Mira El-Khoury et al.|Blood|2022Cited by 46
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemiaVeronika Buxhofer‐Ausch, Heinz Gisslinger, Dominik Wolf et al.|European Journal Of Haematology|2020Cited by 16
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1Sonja Heibl, Josef Thaler, Veronika Buxhofer‐Ausch et al.|Hematological Oncology|2020Cited by 11
Austrian recommendations for the management of essential thrombocythemiaVeronika Buxhofer‐Ausch, Heinz Gisslinger, Sonja Heibl et al.|Wiener klinische Wochenschrift|2020Cited by 2
PS1470 EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIAVeronika Buxhofer‐Ausch, Heinz Gisslinger, Michael Steurer et al.|HemaSphere|2019Cited by 0